Comparing two different sedation techniques (midazolam or no-midazolam) to sedate patients undergoing electrical shock for arrhythmia

Not Applicable

• Conditions: Cardiovascular - Other cardiovascular diseases; Atrial flutter; Atrial fibrillation

• Registration Number: ACTRN12618001122246
• Lead Sponsor: Dr Adam Visser

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-07-06
• Last Update Posted: 22 July 2019

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 102

Inclusion Criteria

Admission to the Critical Care ward for non-emergent cardioversion

Exclusion Criteria

Reduced cardiorespiratory reserve such that a potentially higher dose of propofol required in the absence of midazolam may be detrimental

Contraindiation to use of any of the intended sedative drugs (midazolam, an opiate, propofol)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Requirement for any airway or respiratory support. This is a composite of a number of secondary outcomes.<br><br>This will be assessed by direct observation by a clinician who has received education regarding the trial. Data collection will be performed contemporaneously with the sedation procedure.[During the sedation procedure (approximately ten minutes)];Awareness of electrical shock/pain during cardioversion<br><br>This will be assessed after the sedation procedure has been completed and the patient has recovered enough to be alert without stimulus, and aware of their surroundings. They will be asked if they have any memory of the electrical cardioversion, and if so will be asked how unpleasant it was on a scale from 1 to 10.[This will be assessed between five and sixty minutes after the procedure, after the patient is deemed to have fully recovered from their sedation.]